Anti-EGFR catalytic antibody - Abgenix

Drug Profile

Anti-EGFR catalytic antibody - Abgenix

Alternative Names: EGFR-CA

Latest Information Update: 23 Feb 2005

Price : $50

At a glance

  • Originator Abgenix
  • Class Catalytic antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jun 2004 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 30 Nov 2001 Hesed Biomed has been acquired by Abgenix
  • 22 Nov 1999 EGFR-CA is available for licensing (http://www.hesedbiomed.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top